The development of targeted cancer therapy has benefited greatly from the identification of biomarkers which can provide accurate information on:
• Target engagement – Pharmacodynamic (PD) marker
• Clinical efficacy – Predictive marker
• Adverse effect – Toxicity marker
Leveraging on our predictive models and assets, our signature HuMark® service supports the discovery and validation of PD and predictive biomarkers to guide clinical development, including:
- Whole genome profiling and data analysis
- Next generation genome sequencing
- Mutation analysis Bioinformatics
- In vitro & In vivo PD marker identification click to see an example
- Biomarker assay development & validation click to see an example
- Quantitative Western blot
- Immunohistochemistry click to see an example
- DNA sequencing
